Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms.

ABSTRACT:

Background

Reduced activation of dopamine D₁ receptor signaling may be implicated in reward functioning as a potential driver of negative symptoms in schizophrenia. Phosphodiesterase 10A (PDE10A), an enzyme that is highly expressed in the striatum, modulates both dopamine D₂- and D₁-dependent signaling.

Methods

We assessed whether augmentation of D₁ signaling by the PDE10 inhibitor RG7203 enhances imaging and behavioral markers of reward functions in patients with schizophrenia and negative symptoms. In a 3-period, double-blind, crossover study, we investigated the effects of RG7203 (5 mg and 15 mg doses) and placebo as adjunctive treatment to stable background antipsychotic treatment in patients with chronic schizophrenia with mod

SUBMITTER: Umbricht D 

PROVIDER: S-EPMC9616307 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature